Antimycobacterial activity of UDP-galactopyranose mutase inhibitors. 2010

Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada V5A 1S6.

The galactofuran region of the mycobacterial cell wall consists of alternating 5- and 6-linked beta-d-galactofuranose (beta-D-Galf) residues, essential for viability. UDP-galactofuranose (UDP-Galf), the donor for Galf, is synthesised from UDP-galactopyranose (UDP-Galp) by the enzyme UDP-galactopyranose mutase (UGM), which is not found in humans, rendering it a therapeutic target. The in vitro properties, i.e. enzymatic activity, antimycobacterial activity, cellular toxicity, activity in mycobacterial-infected macrophages and activity against non-replicating persistent mycobacteria, of (4-chlorophenyl)-[1-(4-chlorophenyl)-3-hydroxy-5-methyl-1H-pyrazol-4-yl]-methanone and 3-(4-iodophenyl)-2-[4-(3,4-dichlorophenyl)-thiazol-2-ylamino]-propionic acid were studied. The former compound, a pyrazole, was an inhibitor of UGM from Mycobacterium tuberculosis and Klebsiella pneumoniae and was effective against Mycobacterium smegmatis, Mycobacterium bovis BCG and M. tuberculosis but ineffective against other bacterial strains tested. This compound showed potency against mycobacteria in infected macrophages but exhibited moderate cellular toxicity and was ineffective against non-replicating persistent mycobacteria. This is the first report of a compound both with UGM inhibitory properties and broad antimycobacterial activities. The latter compound, an aminothiazole, was active against UGM from K. pneumoniae and M. tuberculosis but was ineffective against M. bovis BCG or M. tuberculosis as well as demonstrating higher cellular toxicity. These data validate the choice of UGM as a target for active antimycobacterial therapy and confirm the pyrazole compound as a viable lead candidate.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009161 Mycobacterium A genus of gram-positive, aerobic bacteria. Most species are free-living in soil and water, but the major habitat for some is the diseased tissue of warm-blooded hosts. Mycobacteria
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010649 Phenylalanine An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. Endorphenyl,L-Phenylalanine,Phenylalanine, L-Isomer,L-Isomer Phenylalanine,Phenylalanine, L Isomer
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
August 2016, ACS infectious diseases,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
September 2004, Journal of the American Chemical Society,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
May 2008, Journal of the American Chemical Society,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
September 2017, Scientific reports,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
June 2013, Biochemistry,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
March 2018, Scientific reports,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
August 2006, Chemistry & biology,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
October 2015, ACS chemical biology,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
November 2017, Biochemical and biophysical research communications,
Silvia Borrelli, and Wesley F Zandberg, and Sankar Mohan, and Mary Ko, and Fidel Martinez-Gutierrez, and Sarathy Karunan Partha, and David A R Sanders, and Yossef Av-Gay, and B Mario Pinto
March 2018, Journal of cellular biochemistry,
Copied contents to your clipboard!